Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KRYS · NASDAQ · Biotechnology
Krystal Biotech (KRYS) · oqro.io/stocks/KRYS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$308.89−6.93 (−2.19%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Krystal Biotech was filed in the last 90 days. The latest on record was on Oct 18, 2018.
Since 2017, Krystal Biotech insiders reported 11 open-market purchases and 535 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2018.
In the last 90 days, 2 insiders of Krystal Biotech (KRYS) reported 26 open-market sales worth $18M in total on SEC Form 4. The largest seller by value was Krish S Krishnan, with $8.98M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Krystal Biotech (KRYS) was disclosed by a member of Congress in the last 12 months.
Krystal Biotech's next results are expected on Feb 15, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+51.2% (+$104.66) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $204.23 on Nov 20, 2025 to $308.89 on Nov 20, 2026 (+51.2%). Disclosed in this range: 10 insider trades, 132 pre-arranged insider sales, 0 Congress trades, and 22 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Pittsburgh, Pennsylvania.
Last 12 months
+51.3%
Market value
$9.15B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.04M shares sold short (10.3% of shares outstanding), +3.7% vs the previous count, 12.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$389M
+33.9% vs the year before
Net income, fiscal 2025
$205M
As reported in the annual filing
Shares outstanding
29.6M
As of Oct 28, 2026
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Krish S Krishnan (President and CEO) sold ~$1.42M of Krystal Biotech
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$127M
+30.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$310M
This quarter $90.3M, a year earlier $38M
Net debt
—
Debt —, cash $463M, at Sep 30, 2026
Net income, last 12 months
$225M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 2, 2026.
Revenue and earnings history, 10 fiscal yearsRevenue breakdown: where the money goesCompared with its peersEarnings dates and the stock's moves
Against the S&P 500 over the year
Since Nov 19, 2025, KRYS is up 51.3% and the index fund is up 4.1%: 47 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much KRYS moves
Beta 0.7 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insiders of Krystal Biotech reported 11 open-market purchases and 535 sales since 2017; purchases in 2 different years, most recently 2018.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $83.3M110×110 trades |
| 2025 | — | $55M83×83 trades |
| 2024 | — | $77.6M151×151 trades |
| 2023 | — | $66.6M99×99 trades |
| 2022 | — | $14.4M30×30 trades |
| 2021 | — | $21.1M3×3 trades |
| 2020 | — | $11.1M34×34 trades |
| 2019 | — | $9.79M25×25 trades |
| 2018 | $1.95M8×8 trades | — |
| 2017 | $4M3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
1 active phase 3 trial and 4 active phase 2 trials led by this company, mostly in wrinkles in decolletage, dystrophic epidermolysis bullosa, neurotrophic keratitis. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Krystal Biotech over the 12 months to Nov 21, 2026: 2 clinical trials.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
We are a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 17, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Nov 2, 2026
Within the 30 days after it, until Dec 2, 2026
Next results, expected
Feb 15, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Krystal Biotech's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Krystal Biotech's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Fails to deliver: 3,350 shares (about $1.08M) were not delivered on time for settlement on Oct 22, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 38.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (27.0% on ATS, 11.5% with other brokers), below its 26-week average of 41.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (14.4%), SIGMA X2 (11.9%), INTELLIGENT CROSS LLC (9.2%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Feb 17, 2026, compared with the one filed Feb 19, 2025. Read the filing
The information set forth in Note 7 of the Notes to the Consolidated Financial Statements included in Part II Item 8 of this Annual Report on Form 10-K is incorporated by reference into this Item 3.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 17, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.